MX379243B - Fármaco para prevenir y/o tratar la enfermedad renal poliquística. - Google Patents
Fármaco para prevenir y/o tratar la enfermedad renal poliquística.Info
- Publication number
- MX379243B MX379243B MX2019003261A MX2019003261A MX379243B MX 379243 B MX379243 B MX 379243B MX 2019003261 A MX2019003261 A MX 2019003261A MX 2019003261 A MX2019003261 A MX 2019003261A MX 379243 B MX379243 B MX 379243B
- Authority
- MX
- Mexico
- Prior art keywords
- drug
- kidney disease
- polycystic kidney
- preventing
- treating polycystic
- Prior art date
Links
- 208000030761 polycystic kidney disease Diseases 0.000 title abstract 4
- 229940079593 drug Drugs 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 3
- 229940000425 combination drug Drugs 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- GYHCTFXIZSNGJT-UHFFFAOYSA-N tolvaptan Chemical compound CC1=CC=CC=C1C(=O)NC(C=C1C)=CC=C1C(=O)N1C2=CC=C(Cl)C=C2C(O)CCC1 GYHCTFXIZSNGJT-UHFFFAOYSA-N 0.000 abstract 1
- 229960001256 tolvaptan Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Un objeto de la presente invención es proporcionar una combinación de fármacos que tiene notablemente efectos terapéuticos y/o preventivos excelentes en la enfermedad renal poliquística; la presente invención brinda un fármaco para prevenir y/o tratar la enfermedad renal poliquística que comprende una combinación de tolvaptán o uno de sus profármacos con un derivado de somatostatina, y un método para tratar la enfermedad renal poliquística utilizando este fármaco.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261653524P | 2012-05-31 | 2012-05-31 | |
| PCT/JP2013/065637 WO2013180310A1 (en) | 2012-05-31 | 2013-05-30 | Drug for preventing and/or treating polycystic kidney disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX379243B true MX379243B (es) | 2025-03-10 |
Family
ID=48670042
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019003261A MX379243B (es) | 2012-05-31 | 2013-05-30 | Fármaco para prevenir y/o tratar la enfermedad renal poliquística. |
| MX2014014476A MX366121B (es) | 2012-05-31 | 2013-05-30 | Fármaco para prevenir y/o tratar la enfermedad renal poliquística. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014014476A MX366121B (es) | 2012-05-31 | 2013-05-30 | Fármaco para prevenir y/o tratar la enfermedad renal poliquística. |
Country Status (30)
| Country | Link |
|---|---|
| US (8) | US9636382B2 (es) |
| EP (1) | EP2854815B1 (es) |
| JP (4) | JP6116591B2 (es) |
| KR (2) | KR102127180B1 (es) |
| CN (2) | CN104334176B (es) |
| AR (1) | AR091205A1 (es) |
| AU (3) | AU2013268343B2 (es) |
| BR (1) | BR112014029573A2 (es) |
| CA (1) | CA2873365A1 (es) |
| CO (1) | CO7160102A2 (es) |
| CY (1) | CY1120490T1 (es) |
| DK (1) | DK2854815T3 (es) |
| EA (1) | EA036062B1 (es) |
| ES (1) | ES2654768T3 (es) |
| HR (1) | HRP20180040T1 (es) |
| HU (1) | HUE035158T2 (es) |
| IL (2) | IL235623A0 (es) |
| LT (1) | LT2854815T (es) |
| MX (2) | MX379243B (es) |
| MY (1) | MY174625A (es) |
| NO (1) | NO2888775T3 (es) |
| NZ (1) | NZ630118A (es) |
| PH (2) | PH12018501227B1 (es) |
| PL (1) | PL2854815T3 (es) |
| PT (1) | PT2854815T (es) |
| SG (2) | SG11201407368VA (es) |
| SI (1) | SI2854815T1 (es) |
| TW (2) | TWI633887B (es) |
| WO (1) | WO2013180310A1 (es) |
| ZA (1) | ZA201408411B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0918652B1 (pt) | 2008-09-17 | 2021-10-19 | Chiasma, Inc. | Composição farmacêutica compreendendo um meio hidrofóbico e uma forma sólida que compreende polipeptídeo e sal de ácido graxo de cadeia média, processo de produção da mesma e forma de dosagem oral |
| TWI633887B (zh) * | 2012-05-31 | 2018-09-01 | 大塚製藥股份有限公司 | 用於預防及／或治療多囊性腎臟病之藥物 |
| HK1211225A1 (en) * | 2012-12-28 | 2016-05-20 | 大塚制药株式会社 | Injectable depot formulation comprising optically active tolvaptan and process of producing the same |
| TW201605488A (zh) * | 2013-10-15 | 2016-02-16 | 大塚製藥股份有限公司 | 用以預防及／或治療多囊腎病之藥物 |
| HUE071943T2 (hu) | 2015-02-03 | 2025-10-28 | Amryt Endo Inc | Akromegália kezelése oktreotid orális alkalmazásával |
| CA3290933A1 (en) * | 2016-01-21 | 2025-11-29 | Amryt Endo, Inc. | Oral octreotide for the treatment of disease |
| US11547685B2 (en) | 2017-12-11 | 2023-01-10 | Mayo Foundation For Medical Education And Research | Using probenecid to treat polycystic kidney disease |
| GB201905711D0 (en) * | 2019-04-24 | 2019-06-05 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases |
| EP4015860B8 (en) | 2019-08-14 | 2024-10-23 | Autodyn Sys Inc. | Clutch system interlocking with accelerator and brake pedal |
| WO2021075675A1 (ko) | 2019-10-16 | 2021-04-22 | 오토딘시스 주식회사 | 신규한 구조의 회전축 어셈블리 |
| US11141457B1 (en) | 2020-12-28 | 2021-10-12 | Amryt Endo, Inc. | Oral octreotide therapy and contraceptive methods |
| US20230158041A1 (en) * | 2021-11-22 | 2023-05-25 | Otsuka Pharmaceutical Co.,Ltd. | Methods and compositions for treating autosomal dominant polycystic kidney disease |
| WO2025240494A1 (en) | 2024-05-13 | 2025-11-20 | Lumen Bioscience, Inc. | Leptin compositions and methods of making and using the same to support weight loss and/or maintenance |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0450097B1 (en) | 1989-10-20 | 1996-04-24 | Otsuka Pharmaceutical Co., Ltd. | Benzoheterocyclic compounds |
| JP4154765B2 (ja) | 1998-09-28 | 2008-09-24 | ダイキン工業株式会社 | 天井取付型の空気吹出器 |
| GB0018891D0 (en) * | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
| AR044852A1 (es) * | 2003-06-24 | 2005-10-05 | Novartis Ag | Una composicion farmaceutica para la administracion parenteral que comprende un analogo de somatostatina |
| AU2006330277B2 (en) | 2005-12-27 | 2011-10-06 | Otsuka Pharmaceutical Co., Ltd. | Water-soluble benzoazepine compound and its pharmaceutical composition |
| GB0602639D0 (en) | 2006-02-09 | 2006-03-22 | Novartis Ag | Organic compounds |
| EP2007370B1 (en) | 2006-03-31 | 2013-12-18 | Erasmus University Medical Center Rotterdam | Novel composition for tumor growth control |
| JP2009539803A (ja) * | 2006-06-08 | 2009-11-19 | ノバルティス アクチエンゲゼルシャフト | ソマトスタチン−アナログとドーパミン−または成長ホルモン受容体アンタゴニストの組合せ剤 |
| TWI459947B (zh) | 2007-06-26 | 2014-11-11 | Otsuka Pharma Co Ltd | 苯并氮呯化合物及藥學製劑 |
| TWI633887B (zh) | 2012-05-31 | 2018-09-01 | 大塚製藥股份有限公司 | 用於預防及／或治療多囊性腎臟病之藥物 |
-
2013
- 2013-05-21 TW TW102117882A patent/TWI633887B/zh active
- 2013-05-21 TW TW106133192A patent/TWI704919B/zh active
- 2013-05-30 AR ARP130101890 patent/AR091205A1/es unknown
- 2013-05-30 BR BR112014029573A patent/BR112014029573A2/pt not_active IP Right Cessation
- 2013-05-30 EP EP13730377.2A patent/EP2854815B1/en active Active
- 2013-05-30 HU HUE13730377A patent/HUE035158T2/hu unknown
- 2013-05-30 AU AU2013268343A patent/AU2013268343B2/en active Active
- 2013-05-30 CN CN201380028294.2A patent/CN104334176B/zh active Active
- 2013-05-30 CA CA2873365A patent/CA2873365A1/en not_active Abandoned
- 2013-05-30 NZ NZ630118A patent/NZ630118A/en unknown
- 2013-05-30 US US14/402,540 patent/US9636382B2/en active Active
- 2013-05-30 MY MYPI2014703474A patent/MY174625A/en unknown
- 2013-05-30 ES ES13730377.2T patent/ES2654768T3/es active Active
- 2013-05-30 DK DK13730377.2T patent/DK2854815T3/en active
- 2013-05-30 KR KR1020147036458A patent/KR102127180B1/ko active Active
- 2013-05-30 MX MX2019003261A patent/MX379243B/es unknown
- 2013-05-30 JP JP2014555000A patent/JP6116591B2/ja active Active
- 2013-05-30 PL PL13730377T patent/PL2854815T3/pl unknown
- 2013-05-30 HR HRP20180040TT patent/HRP20180040T1/hr unknown
- 2013-05-30 SG SG11201407368VA patent/SG11201407368VA/en unknown
- 2013-05-30 EA EA201492279A patent/EA036062B1/ru not_active IP Right Cessation
- 2013-05-30 WO PCT/JP2013/065637 patent/WO2013180310A1/en not_active Ceased
- 2013-05-30 KR KR1020207008076A patent/KR102211354B1/ko active Active
- 2013-05-30 PT PT137303772T patent/PT2854815T/pt unknown
- 2013-05-30 SI SI201330909T patent/SI2854815T1/en unknown
- 2013-05-30 CN CN201710751329.5A patent/CN107625953A/zh active Pending
- 2013-05-30 PH PH1/2018/501227A patent/PH12018501227B1/en unknown
- 2013-05-30 SG SG10201609250QA patent/SG10201609250QA/en unknown
- 2013-05-30 MX MX2014014476A patent/MX366121B/es active IP Right Grant
- 2013-05-30 LT LTEP13730377.2T patent/LT2854815T/lt unknown
- 2013-08-23 NO NO13830513A patent/NO2888775T3/no unknown
-
2014
- 2014-11-11 IL IL235623A patent/IL235623A0/en unknown
- 2014-11-17 PH PH12014502558A patent/PH12014502558A1/en unknown
- 2014-11-17 ZA ZA2014/08411A patent/ZA201408411B/en unknown
- 2014-12-29 CO CO14284574A patent/CO7160102A2/es unknown
-
2015
- 2015-11-09 US US14/935,592 patent/US9669075B2/en active Active
-
2017
- 2017-02-13 JP JP2017024505A patent/JP2017110029A/ja active Pending
- 2017-03-29 US US15/473,032 patent/US20170196877A1/en not_active Abandoned
- 2017-04-27 AU AU2017202757A patent/AU2017202757A1/en not_active Abandoned
- 2017-05-05 US US15/587,976 patent/US20170239265A1/en not_active Abandoned
- 2017-07-12 IL IL253441A patent/IL253441A0/en unknown
-
2018
- 2018-01-16 CY CY20181100047T patent/CY1120490T1/el unknown
- 2018-08-21 JP JP2018154519A patent/JP6724085B2/ja active Active
- 2018-12-19 US US16/225,255 patent/US11147821B2/en active Active
-
2019
- 2019-01-17 US US16/250,100 patent/US11013746B2/en active Active
- 2019-03-28 AU AU2019202158A patent/AU2019202158B2/en active Active
-
2020
- 2020-04-13 JP JP2020071399A patent/JP6938705B2/ja active Active
-
2021
- 2021-09-15 US US17/475,451 patent/US11957691B2/en active Active
-
2024
- 2024-03-13 US US18/604,451 patent/US20240216389A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014502558B1 (en) | Drug for preventing and/or treating polycystic kidney disease | |
| PH12014502704A1 (en) | Compounds and compositions for modulating egfr activity | |
| GB2541571A (en) | Pharmaceutical compositions | |
| GB201103062D0 (en) | Method | |
| MX2014010455A (es) | Metodos y composiciones para tratar enfermedad de huntington. | |
| CR20120202A (es) | Métodos y composiciones para tratar cáncer | |
| SG10201903119QA (en) | Polypeptide vaccine | |
| WO2013134336A3 (en) | Inhibition of adaptor associated kinase 1 for the treatment of pain | |
| UA118759C2 (uk) | Сполуки 3,4-дигідроізохінолін-2(1н)-ілу | |
| WO2014165090A8 (en) | Compounds for the treatment of tuberculosis | |
| PH12014502032A1 (en) | Treatment of brain cancer | |
| NZ722600A (en) | Methods of treating mild brain injury | |
| PH12017500459A1 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
| AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
| MX2017016114A (es) | Metodos para tratar o prevenir una proteopatia. | |
| GEP20186920B (en) | Halogenated quinazolinthf-amines as pde1 inhibitors | |
| WO2014149139A3 (en) | Halogenopyrazoles as inhibitors of thrombin | |
| PH12014502065A1 (en) | Vesicular formulations | |
| EP2994156A4 (en) | Compounds, compositions and methods for the treatment of diseases through inhibiting tgf- activity | |
| IN2013MU02509A (es) | ||
| WO2016164719A3 (en) | Methods used to treat cancer | |
| GB2546703A (en) | Compounds | |
| HK1207008A1 (en) | Use of thymosin alpha for treatment of purulent rhinosinusitis |